These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36699027)

  • 41. The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type-2 inhibitors: real-world study.
    Paul SK; Bhatt DL; Montvida O
    Eur Heart J; 2021 May; 42(18):1728-1738. PubMed ID: 33289789
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study.
    Kosiborod M; Lam CSP; Kohsaka S; Kim DJ; Karasik A; Shaw J; Tangri N; Goh SY; Thuresson M; Chen H; Surmont F; Hammar N; Fenici P;
    J Am Coll Cardiol; 2018 Jun; 71(23):2628-2639. PubMed ID: 29540325
    [TBL] [Abstract][Full Text] [Related]  

  • 43. SGLT-2 inhibitors and cardiovascular outcomes in patients with and without a history of heart failure: a systematic review and meta-analysis.
    Razuk V; Chiarito M; Cao D; Nicolas J; Pivato CA; Camaj A; Power D; Beerkens F; Jones D; Alter A; Mathew A; Spirito A; Contreras JP; Dangas GD; Mehran R
    Eur Heart J Cardiovasc Pharmacother; 2022 Sep; 8(6):557-567. PubMed ID: 35021205
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Should Baseline Hemoglobin A
    Uhrig JL; Page SO; Mishriky BM; Patil SP; Powell JR; Sewell K; Mian MR; Cummings DM
    J Clin Pharmacol; 2020 Aug; 60(8):980-991. PubMed ID: 32396236
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Association of Sodium-Glucose Cotransporter-2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes.
    Zhuo M; Hawley CE; Paik JM; Bessette LG; Wexler DJ; Kim DH; Tong AY; Kim SC; Patorno E
    JAMA Netw Open; 2021 Oct; 4(10):e2130762. PubMed ID: 34705014
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Relationship between sodium-glucose cotransporter-2 inhibitors and muscle atrophy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
    Xia C; Han Y; Yin C; Geng R; Liu Z; Du Y; Yu M
    Front Endocrinol (Lausanne); 2023; 14():1220516. PubMed ID: 37780608
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Meta-analysis of the effects of sodium glucose cotransporter 2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes.
    Sinha B; Datta D; Ghosal S
    JGH Open; 2021 Feb; 5(2):219-227. PubMed ID: 33553659
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effect of sodium-glucose cotransporter 2 inhibitors on left cardiac remodelling in heart failure with reduced ejection fraction: Systematic review and meta-analysis.
    Usman MS; Januzzi JL; Anker SD; Salman A; Parikh PB; Adamo M; Filippatos G; Khan MS; Lala A; Verma S; Metra M; Butler J
    Eur J Heart Fail; 2024 Feb; 26(2):373-382. PubMed ID: 38235936
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Beneficial effects of sodium glucose cotransporter 2 inhibitors on left ventricular mass in patients with diabetes mellitus.
    Kosugi D; Inaba H; Kaido Y; Ito S; Hirobata T; Toyofuku M; Matsuoka T; Inoue G
    J Diabetes; 2021 Nov; 13(11):847-856. PubMed ID: 34231959
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Association of Sodium-Glucose Cotransporter-2 Inhibitors With Incident Atrial Fibrillation in Older Adults With Type 2 Diabetes.
    Zhuo M; D'Andrea E; Paik JM; Wexler DJ; Everett BM; Glynn RJ; Kim SC; Patorno E
    JAMA Netw Open; 2022 Oct; 5(10):e2235995. PubMed ID: 36219443
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of SGLT-2 inhibitors on adipose tissue distribution in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials.
    Wang X; Wu N; Sun C; Jin D; Lu H
    Diabetol Metab Syndr; 2023 May; 15(1):113. PubMed ID: 37254186
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial.
    Connelly KA; Mazer CD; Puar P; Teoh H; Wang CH; Mason T; Akhavein F; Chang CW; Liu MH; Yang NI; Chen WS; Juan YH; Opingari E; Salyani Y; Barbour W; Pasricha A; Ahmed S; Kosmopoulos A; Verma R; Moroney M; Bakbak E; Krishnaraj A; Bhatt DL; Butler J; Kosiborod MN; Lam CSP; Hess DA; Rizzi Coelho-Filho O; Lafreniere-Roula M; Thorpe KE; Quan A; Leiter LA; Yan AT; Verma S
    Circulation; 2023 Jan; 147(4):284-295. PubMed ID: 36335517
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of Ramadan fasting in patients with type 2 diabetes mellitus treated with sodium-glucose cotransporter 2 inhibitors: A systematic review and meta-analysis.
    Gad H; Al-Nassr N; Mohammed I; Khan A; MacDonald R; Mussleman P; Malik RA
    J Diabetes Investig; 2022 May; 13(5):822-829. PubMed ID: 34953158
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Glucagon-like-1 receptor agonists and sodium/glucose cotransporter-2 inhibitors combination-are we exploiting their full potential in a real life setting?
    Berkovic MC; Bilic-Curcic I; Bozek T; Mahecic DH; Majanovic SK; Canecki-Varzic S; Andric J; Marusic S; Mrzljak A
    World J Diabetes; 2020 Nov; 11(11):540-552. PubMed ID: 33269065
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lower heart failure and chronic kidney disease risks associated with sodium-glucose cotransporter-2 inhibitor use in Japanese type 2 diabetes patients without established cardiovascular and renal diseases.
    Komuro I; Kadowaki T; Bodegård J; Thuresson M; Okami S; Yajima T
    Diabetes Obes Metab; 2021 Apr; 23 Suppl 2():19-27. PubMed ID: 33835641
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Features of left ventricular hypertrophy in patients with metabolic syndrome with or without comparable blood pressure: a meta-analysis.
    Li NY; Yu J; Zhang XW; Wang SX; Chang P; Ding Q; Ma RX; Chen QF; Zhao F; Bai F
    Endocrine; 2013 Jun; 43(3):548-63. PubMed ID: 23371816
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Systematic Review and Meta-Analysis: Safety and Efficacy of Mesenchymal Stem Cells Therapy for Heart Failure.
    Shen T; Xia L; Dong W; Wang J; Su F; Niu S; Wang Q; Fang Y
    Curr Stem Cell Res Ther; 2021; 16(3):354-365. PubMed ID: 32867655
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Type 2 diabetes and risk of heart failure: a systematic review and meta-analysis from cardiovascular outcome trials.
    Giugliano D; Maiorino MI; Longo M; Bellastella G; Chiodini P; Esposito K
    Endocrine; 2019 Jul; 65(1):15-24. PubMed ID: 31028667
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study.
    Lugner M; Sattar N; Miftaraj M; Ekelund J; Franzén S; Svensson AM; Eliasson B
    Cardiovasc Diabetol; 2021 Mar; 20(1):67. PubMed ID: 33752680
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
    Palmer SC; Tendal B; Mustafa RA; Vandvik PO; Li S; Hao Q; Tunnicliffe D; Ruospo M; Natale P; Saglimbene V; Nicolucci A; Johnson DW; Tonelli M; Rossi MC; Badve SV; Cho Y; Nadeau-Fredette AC; Burke M; Faruque LI; Lloyd A; Ahmad N; Liu Y; Tiv S; Millard T; Gagliardi L; Kolanu N; Barmanray RD; McMorrow R; Raygoza Cortez AK; White H; Chen X; Zhou X; Liu J; Rodríguez AF; González-Colmenero AD; Wang Y; Li L; Sutanto S; Solis RC; Díaz González-Colmenero F; Rodriguez-Gutierrez R; Walsh M; Guyatt G; Strippoli GFM
    BMJ; 2021 Jan; 372():m4573. PubMed ID: 33441402
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.